Feb 2 2012
In her "Global Health Blog," Guardian health editor Sarah Boseley speaks with GlaxoSmithKline CEO Andrew Witty about the year-long efforts to bring together the heads of more than a dozen pharmaceutical companies in a large public-private initiative to control or eliminate neglected tropical diseases (NTDs). "In terms of what should this industry be doing preferentially, it should be making available the drugs which nobody else has for people in these countries who suffer from these diseases ... and we should be committing ourselves to discover more, better drugs for the future, and we're doing that today and we're collaborating with others to make it happen quicker," Witty said (1/31).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |